Marini Massimiliano, Ravanelli Daniele, Martin Marta, Battisti Valentina, Quintarelli Silvia, Guarracini Fabrizio, Coser Alessio, Menegotti Loris, Bonmassari Roberto
Department of Cardiology S. Chiara Hospital Trento Italy.
Department of Physics S. Chiara Hospital Trento Italy.
J Arrhythm. 2020 Jun 30;36(4):720-726. doi: 10.1002/joa3.12387. eCollection 2020 Aug.
Three-dimensional (3D) nonfluoroscopic mapping systems (NMSs) are generally used during the catheter ablation (CA) of complex arrhythmias. We evaluated the efficacy, safety, and economic advantages of using NMSs during His-Bundle CA (HB-CA).
A total of 124 consecutive patients underwent HB-CA between 2012 and 2019 in our EP Laboratory. We compared two groups: 63 patients who underwent HB-CA with fluoroscopy alone from 2012 to 2015 (Group I) and 61 patients who underwent HB-CA with the aid of NMSs from 2016 to 2019 (Group II). Two cost-effectiveness analyses were carried out: the alpha value (AV) (ie, a monetary reference value of the units of exposure avoided, expressed as $/man Sievert) and the value of a statistical life (VSL) (ie, the amount of money that a community would be willing to pay to reduce the risk of a person's death owing to exposure to radiation, it is not the cost value of a person's life). The cost reduction estimated by means of both these methods was compared with the real additional cost of using NMSs.
The use of NMS resulted in reduced fluoroscopy time in Group II {median 1.35 min} in comparison with Group I {median 4.8 min ( < .05)}. The effective dose reduction (ΔE) was 1.16 milli-Sievert.
The use of NMS significantly reduces fluoroscopy time. However, the actual reduction is modest and in our EP Laboratory this reduction is not cost-effective. Indeed, when the ΔE is referred to country and agency tables for absolute values of AV or VLS, it is not economically advantageous in almost all cases.
三维(3D)非荧光透视标测系统(NMSs)通常用于复杂心律失常的导管消融(CA)。我们评估了在希氏束导管消融(HB-CA)过程中使用NMSs的有效性、安全性和经济优势。
2012年至2019年期间,共有124例连续患者在我们的电生理实验室接受了HB-CA。我们比较了两组:2012年至2015年仅使用荧光透视进行HB-CA的63例患者(第一组)和2016年至2019年借助NMSs进行HB-CA的61例患者(第二组)。进行了两项成本效益分析:α值(AV)(即避免暴露单位的货币参考值,以美元/人西弗表示)和统计生命价值(VSL)(即社区为降低因辐射暴露导致的人员死亡风险而愿意支付的金额,它不是一个人的生命成本价值)。通过这两种方法估计的成本降低与使用NMSs的实际额外成本进行了比较。
与第一组{中位数4.8分钟}相比,第二组使用NMS导致荧光透视时间减少{中位数1.35分钟(<0.05)}。有效剂量降低(ΔE)为1.16毫西弗。
使用NMS可显著减少荧光透视时间。然而,实际减少幅度不大,在我们的电生理实验室中,这种减少并不具有成本效益。实际上,当将ΔE参考国家和机构的AV或VLS绝对值表时,在几乎所有情况下在经济上都不具有优势。